Pre-eclampsia is associated with complement pathway activation in the maternal and fetal circulation, and placental tissue.
Biomarkers
Complement system proteins
Placenta
Pre-eclampsia
Pregnancy
Journal
Pregnancy hypertension
ISSN: 2210-7797
Titre abrégé: Pregnancy Hypertens
Pays: Netherlands
ID NLM: 101552483
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
09
09
2022
revised:
21
02
2023
accepted:
11
04
2023
medline:
29
5
2023
pubmed:
24
4
2023
entrez:
23
04
2023
Statut:
ppublish
Résumé
Pre-eclampsia (PE) is a leading cause of obstetric morbidity, with no definitive therapy other than delivery. We aimed to compare complement markers in maternal and fetal circulation, and placental tissue, between women with PE and healthy pregnant controls. Maternal and umbilical cord blood was tested for iC3b, C3, C4, properdin, Ba and C5b-9, and placental tissue for C3d, C4d, C9 and C1q, from women with PE (n = 34) and healthy pregnant controls (n = 33). Maternal properdin and Ba tests were repeated in a separate validation cohort (PE n = 35; healthy pregnant controls n = 35). Complement concentrations in maternal and umbilical cord blood, and placental immunohistochemical complement deposition. Women with PE had significantly lower concentrations of properdin (mean: 4828 vs 6877 ng/ml, p < 0.001) and C4 (mean: 0.20 vs 0.31 g/l, p < 0.001), and higher Ba (median: 150 vs 113 ng/ml, p = 0.012), compared to controls. After controlling for gestational age at blood draw, average properdin concentration was 1945 ng/ml lower in PE vs controls (95 % CI: 1487-2402, p < 0.001). Of the cord blood markers assessed, only Ba differed significantly between PE and controls (median: 337 vs 233 ng/ml, p = 0.004). C4d staining of the syncytiotrophoblast membrane was increased in PE vs controls (median immunoreactivity score 3 vs 0, p < 0.001). Maternal properdin and C4 were significantly negatively correlated with placental C4d staining. Our data confirm excessive placental complement deposition associated with significant concurrent changes in maternal and fetal circulating complement biomarkers in PE. Inhibition of complement activation is a potential therapeutic target.
Identifiants
pubmed: 37088032
pii: S2210-7789(23)00018-1
doi: 10.1016/j.preghy.2023.04.001
pii:
doi:
Substances chimiques
Properdin
11016-39-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
43-49Informations de copyright
Crown Copyright © 2023. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.